Read today’s Kaiser Health News
In other news:
About health insurance/insurers
Humana posts $1.2B profit in Q1: Humana recorded a net income of $1.2 billion in the first quarter of 2025, up from a net income of $741 million during the same period last year, according to its April 30 financial report.
Total revenue for the three months ended March 31 was $32.1 billion, up from $29.6 billion during the same quarter last year.
Humana reported total operating expenses of $30.1 billion in the first quarter, up from $28.4 billion.
The payer’s medical loss ratio was 87.4% in the first quarter of 2025. The company expects a medical loss ratio between 90.1% and 90.5% for the full year.
Omnicare Hit With $136M Jury Verdict For Bilking Feds: A New York federal jury on Tuesday returned a verdict finding that CVS Health Corp. subsidiary Omnicare illegally billed the federal government to the tune of $135.6 million, one of the largest jury verdicts in a False Claims Act case…
About pharma
Mark Cuban’s drug company leans further into specialty market: Mark Cuban Cost Plus Drug Co. has secured another partnership targeting the specialty pharmaceutical market, according to an April 28 news release shared with Becker’s.
EverPharm, a specialty unit-dose medication company, is joining its portfolio with Cost Plus Drugs’ pricing model, which is the drug’s manufacturing cost plus a 15% markup and a $10 shipping and labor fee. On April 16, Cost Plus Drugs launched a similar partnership with Morris & Dickson, a full-line and specialty pharmaceutical distributor.
About healthcare IT
Healthcare data breaches, by the numbers: Here are five things to know from Verizon Business’ 2025 Data Breach Investigations Report, released April 23:
1. Healthcare had 1,542 data breaches from late 2023 to late 2024, an increase from the year prior.
2. System intrusion was the top kind of breach.
3. Of the threat actors, 67% were external while 30% were internal.
4. Financial interest was the No. 1 motive (90%) of hackers.
5. The top data compromised were medical (45%) and personal (40%).
About health technology
Generalizability of FDA-Approved AI-Enabled Medical Devices for Clinical Use: In this cross-sectional study, clinical performance studies at the time of approval were reported for approximately half of AI-enabled medical devices, yet the information was often insufficient for a comprehensive assessment of their clinical generalizability, emphasizing the need for ongoing monitoring and regular re-evaluation to identify and address unexpected performance changes during broader use.